海创药业: 2025年半年度募集资金存放与实际使用情况的专项报告

Summary of Key Points Core Viewpoint - Haichuang Pharmaceutical Co., Ltd. has provided a detailed report on the management and usage of raised funds as of June 30, 2025, highlighting the total amount raised, its allocation, and the management protocols in place to ensure compliance and security of the funds [1][2]. Fundraising Overview - The company raised a total of RMB 1,062,699,200.00 through the issuance of 24,760,000 shares at RMB 42.92 per share, with a net amount of RMB 995,113,315.68 after deducting issuance costs [1][2]. - As of June 30, 2025, the cumulative usage of the raised funds amounted to RMB 871,447,067.89, leaving a balance of RMB 147,244,678.39, which includes RMB 23,578,430.60 from cash management [1][2]. Fund Management Practices - The company has established a fundraising management system to regulate the storage, management, and usage of the raised funds, ensuring compliance with relevant regulations [1][2]. - A tripartite supervision agreement has been signed with the underwriter and banks to clarify the rights and obligations of all parties involved in the management of the funds [1][2]. Actual Usage of Funds - The report indicates that there were no instances of using raised funds to replace pre-invested amounts or to temporarily supplement working capital during the reporting period [2][3]. - The company has approved the use of up to RMB 170 million of temporarily idle funds for cash management, investing in high-security and liquid financial products [2][3]. Project Delays and Adjustments - The company has postponed the completion date for certain fundraising projects, including the "R&D Production Base Construction Project" to December 31, 2025, and parts of the "Innovative Drug R&D Project" to December 31, 2026, due to implementation progress considerations [2][3]. - No changes have been made to the investment projects or their total amounts, ensuring that the adjustments do not adversely affect the company's operations or shareholder interests [3][4].